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Diffuse gliomas consist of both low- and high-grade varieties, each with distinct morphological and biological features. The often
extended periods of relative indolence exhibited by low-grade gliomas (LGG; WHO grade II) differ sharply from the aggressive, rapidly
fatal clinical course of primary glioblastoma (GBM; WHO grade IV). Nevertheless, until recently, the molecular foundations underlying
this stark biological contrast between glioma variants remained largely unknown. The discoveries of distinctive and highly recurrent
genomic and epigenomic abnormalities in LGG have both informed a more accurate classification scheme and pointed to viable
avenues for therapeutic development. As such, the field of neuro-oncology now seems poised to capitalize on these gains to achieve sig-
nificant benefit for LGG patients. This report will briefly recount the proceedings of a workshop held in January 2013 and hosted by Ac-
celerate Brain Cancer Cure (ABC2) on the subject of LGG. While much of the meeting covered recent insights into LGG biology, its focus
remained on how best to advance the clinical management, whether by improved preclinical modeling, more effective targeted thera-
peutics and clinical trial design, or innovative imaging technology.
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Diffuse gliomas of adulthood are unified by a shared propensity to
widely infiltrate surrounding normal brain parenchyma, a property
that effectively renders them incurable. However, the full spectrum
of diffuse glioma features considerable clinical heterogeneity. More
specifically, patients with glioblastoma (GBM; WHO grade IV) dem-
onstrate overall survival times of 15 months,1 while those
affected by low-grade (WHO grade II) astrocytomas and oligo-
dendrogliomas frequently exhibit prolonged clinical courses
lasting years or even decades.2 Low-grade gliomas (LGGs) almost
invariably recur and progress to high-grade status (WHO grade
III-IV). Nevertheless, their characteristically extended periods of
indolence would seem to invite targeted intervention with “de-
signer therapeutics” as an option for long-term disease control.
In this way, LGGs would not simply be managed as “GBMs in
waiting” and would instead drive distinct algorithms for clinical
management.
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Until quite recently, the systematic study of LGGs has been hin-
dered by the somewhat subjective histopathological criteria by
which specific diagnostic categories were designated, coupled with
the lackof well-defined molecular drivers for the tumors themselves.
Recent advances in the genomic characterization of LGGs, notably
the discoveries of pathogenic mutations in IDH1, IDH2, ATRX, CIC,
and FUBP1, have both clarified the molecular pathogenesis of
these tumors and established robust markers for their classifica-
tion.3–9 Now more than ever, the field of neuro-oncology seems
poised for tangible gains in the development and refinement of cus-
tomized treatment strategies for LGG. In light of these significant
developments, a small group of neuro-oncologists, neurosurgeons,
neuropathologists, radiation oncologists, and basic scientists gath-
ered in Sausalito,California, in January 2013 for a meeting sponsored
by Accelerate Brain Cancer Cure (ABC2) in collaboration with the Uni-
versityof California, San Francisco, and the Universityof Texas MDAn-
derson Cancer Center. The primary aim of the 2-day conference,
entitled the “Low Grade Glioma Research Workshop,” was to
assess the evolving landscape of basic and clinical research on
LGGs with an eye towards optimizing preclinical testing and thera-
peutic trials moving forward. This report will describe the essentials
of the various presentations and discuss some of the central
themes emerging from the workshop that are likely to guide forth-
coming investigative efforts.
Optimizing Current Treatment Modalities for
Low-grade Giloma
While the clinical management of GBM has become highly standar-
dized during the past decade, well-defined protocols for the treat-
ment of LGG are lacking. Of note, considerable uncertainty
remains regarding the most appropriate use of surgery, ionizing ra-
diation (IR), and cytotoxic chemotherapy, all of which are mainstays
in the treatment ofGBM.Several talks at the LGG Research Workshop
spoke directly to open questions such asthese. Mitch Berger (Univer-
sity of California, San Francisco) described recent work demonstrat-
ing that the extent of surgical resection can strongly impact LGG
patient outcome.10 In particular, gross total resections resulted in
extended progression-free survival (PFS), not infrequently exceeding
10 years. His findings support more aggressive resection of LGGs
upfront, employing detailed cortical mapping as needed to facilitate
thorough dissection in eloquent brain regions.
Determining the optimal clinical context for radiotherapy in the
management of LGG represents an additional challenge for the
field. In her talk on this subject, Daphne Haas-Kogan (University
of California, San Francisco) highlighted data from EORTC (Euro-
pean Organisation for Research and Treatment of Cancer) 22845
indicating that early postoperative radiotherapy delays LGG pro-
gression but does not appear to impact overall survival (see Table
1 for information on clinical trials disussed in this report).11 More-
over, results from EORTC 22844 showed no evidence of increased
efficacy for higher doses of IR compared with lower doses.12 She
also discussed which patients should receive IR in the post-
operative setting, arguing that indications for treatment include
progressive disease after observation, significant, new or worsen-
ing neurological symptoms, age .40 years, and poorly controlled
seizures. That being said, she described data from RTOG (Radiation
Therapy Oncology Group) 9802 and 0925 indicating that simple
observation may be an acceptable, if not necessarily superior,
course of action for some LGGs.13
Riccardo Soffietti (University Hospital, Turin) reviewed a number
of issues surrounding the usage of chemotherapy in LGG patients.
He cited early data from RTOG 9802 suggesting that procarbazine,
N-(2-chloroethyl)-N′-cyclohexyl-N-nitrosourea, and vincristine
(PCV) chemotherapy, combined with ionizing radiation, thus far
improves PFS in LGG patients but not overall survival.13 He also dis-
cussed ongoing EORTC and RTOG trials, which should provide
further clarification as to whether temozolomide alone or con-
comitant radiotherapy and temozolomide represent superior
upfront treatment regimens to radiotherapy alone. Moreover, he
argued that chemotherapy alone may itself play an important
role in symptomatic reduction for LGG, particularly in the setting
of seizures, while temporarily sparing patients radiotherapy to
the CNS and its associated risk of cognitive deficits.14,15
Multiple speakers stressed the importance of radiographic as-
sessment, particularly in the determination of malignant progres-
sion and therapeutic response, and the considerable challenges
posed by LGGs in this regard. Dan Cahill (Massachusetts General
Hospital) spoke directly to this issue, emphasizing that for LGGs in
particular, infiltrative growth patterns, pseudoprogression, and diffi-
culties distinguishing symptoms arising from tumor growth from
those arising from treatment side effects complicate the integration
of radiographic findings with clinical status. Moreover, he argued
that standard paradigms correlating contrast enhancement with
malignant progression may be inadequate for the effective assess-
ment of LGGs, especially the large majorityharboring IDH mutations
(see below) whose fundamental biology differs sharply from that of
primary GBM. Finally, he cited 2 studies whose findings indicated
that, as a consequence of intratumoral heterogeneity, surgical
undersampling can result in diagnoses not reflective of the tumor
as a whole,16,17 and suggested that focused magnetic resonance
spectroscopy could greatly facilitate the selection of more appropri-
ate biopsy targets.
Emerging Molecular Foundations of Low-grade Glioma
As alluded to above, genomic profiling efforts have revealed a
defined set of molecular abnormalities occurring at high rates in
LGG that by contrast are largely absent in primary GBM. Indeed, re-
centlydiscoveredsomaticmutations in IDH1/2, ATRX, CIC, and FUBP1
have dramatically altered conceptions of low-grade gliomagenesis
while also informing more robust diagnostic classification
schemes (Fig. 1). A number of talks at the LGG Research Workshop
covered recent work identifying and characterizing these genomic
events. Mutations in IDH1 and its homologue IDH2 have been
shown to occur in 70%–90% of LGGs and the higher-grade
tumors into which they evolve.7,8 Through production of the onco-
metabolite R(-)-2-hydroxy-glutarate (2HG), IDH mutations appear
to dysregulate cellular epigenomic landscapes, hamper normal dif-
ferentiation processes, and impede the tumor-suppressive func-
tions of HIF1a, all of which likely contribute to the initiation of
gliomagenesis.18–22 Ken Aldape (MD Anderson Cancer Center)
described a series of studies examining how IDH mutational
status correlated with histopathological features and clinical
outcome in both WHO grade II and WHO grade III diffuse
gliomas. Using a cohort of 559 tumors consisting of both astrocytic
and oligodendroglial glioma subtypes, his group found that IDH mu-
tational status clearly outperformed standard WHO histopatho-
logical grading in terms of prognostic stratification, with mutant
tumors exhibiting better prognosis, which was consistent with
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previous reports.8,23–25 Moreover, histopathological features,
whether standard WHO grading metrics or measures of proliferative
activity (eg, pHH3 immunohistochemistry), demonstrated little if
any association with clinical outcome for IDH-mutant tumors,
which also echoed findings from earlier work.23 By contrast, prolif-
erative activity was highly predictive in IDH-wt tumors designating
an aggressive “GBM-like” subset.
IDH-mutant LGGs harbor additional highly recurrent molecular
abnormalities that correlate with tumor morphology. For instance,
it has long been appreciated that coincident loss of chromosomes
1p and 19q by way of a unique translocation event—t(1;19)
(q10;p10)—is highly enriched in oligodendroglioma26,27 and that
this genomic abnormality may silence crucial, disease-relevant
tumor suppressors. This latter conjecture implies that 1p/19q code-
leted gliomas may also harbor inactivating mutations in putative
tumor suppressors on undeleted copies of chromosomes 1p and
19q. Stephen Yip (Vancouver General Hospital) and Chetan Bette-
gowda (Johns Hopkins Medical Institutions) each presented
results from recent deep sequencing studies exploring this hypoth-
esis.3,9 In both cases, mutations in the CIC gene on chromosome
19q and, to a lesser extent the FUBP1 gene on chromosome 1p,
were found to be highly enriched in 1p/19q codeleted LGGs. Dr. Yip
also described work identifying promoter hypermethylation at the
NHE-1 locus on chromosome 1p as a frequent occurrence in this
tumor subset.28 While the precise functional roles of CIC, FUBP1,
and NHE-1 in normal cell biology, as well as the consequences of
their deficiency on gliomagenic transformation, are unclear, intri-
guing associations with oncogenic signaling networks and gene
regulation provide exciting avenues for future investigations.
Dr. Bettegowda also reviewed several recent reports describing
loss-of-function ATRX mutations in the majority of IDH-mutant,
1p/19q-intact LGGs, predominantly those exhibiting astrocytic
morphology.4 –6 ATRX is involved in the maintenance and remodel-
ing of chromatin, particularly at heterochromatic regions like telo-
meres.29 ATRX deficiency appears to induce pathological telomere
maintenance via so-called “alternative lengthening of telomeres”
(ALT), a potential molecular mechanism enabling cellular immortal-
ization.30 As an aside, more recent data have demonstrated that ac-
tivatingpromotermutations inTERT, thecore enzymatic component
of telomerase, are mutually exclusive with ATRX mutations in IDH-
mutant LGGs (occurring primarily in the context of 1p/19q codele-
tion), further supporting the notion that pathological telomere
maintenance is required for the pathogenesis of these tumors.31
Whether ALT or any other physiological sequelae of ATRX mutation
mediates low-grade gliomagenesis remains to be established. Re-
gardless, the mutual exclusivity that exists between ATRX and CIC/
FUBP1 mutations in IDH-mutant LGGs forms the foundation of an
improved classification scheme (Fig. 1). Emphasizing this, Dr. Bette-
gowda presented survival data showing that IDH-mutant, CIC/
FUBP1-mutant gliomas performed significantly better than IDH-
mutant, ATRX-mutant gliomas, with both groups demonstrating
favorable prognosis relative to their IDH-wt counterparts.4
The Cancer Genome Atlas (TCGA) has recently embarked on a
large-scale, multidimensional, molecular analysis of LGG. Dan
Brat (Emory University), who heads the effort, and Sofie Salama
(University of California, Santa Cruz) provided a general overview
of the project and described preliminary data emerging from the
various profiling pipelines. While much work remains to be done,
early findings have confirmed the pervasive occurrence and coex-
istent patterns of IDH1/2, ATRX, CIC, and FUBP1 mutations. More-
over, IDH mutation associates with a CpG island hypermethylator
phenotype, as expected, with IDH-wt LGGs standing out as a dis-
tinctly hypomethylated subgroup whose genomic profile strikingly
resembles that of primary GBM (eg, common copy number altera-
tions in chromosomes 7 and 10). Gene expression clusters that cor-
relate with genomic and epigenomic signatures are also emerging.
Further results from TCGA will be highly anticipated by the
neuro-oncology community, with the first report expected in the
spring/summer of 2014.
Preclinical Modeling of Low-grade Glioma
As research into LGG continues to reveal promising therapeutic
strategies, the need for robust preclinical models will only continue
to grow. And while many such experimental systems, both in vitro
and in vivo, currently exist for GBM, their specific development for
the study of LGG has lagged far behind. This challenge was dis-
cussed explicitly at the LGG Research Workshop. C Ryan Miller (Uni-
versity of North Carolina, Chapel Hill) discussed a series of
genetically engineered mouse models, recently produced by his
lab, that appear to recapitulate the core biological features of
LGG with periods of relative indolence followed by high-grade
transformation; this despite their derivation from molecularabnor-
malities classically associated with GBM, namely retinoblastoma
(RB) dysfunction, PTEN loss, and RAS/MAPK pathway activation.
He found that the gene expression patterns of the various
models segregated not only with specific molecular drivers of
tumorigenesis but also tended to reflect cell of origin. He observed
that the majority of WHO grade II tumors emerging from his
Fig. 1. Molecular subclasses of diffuse glioma. IDH-wt tumors frequently
exhibit receptor tyrosine kinase (RTK) amplification and/or mutation and
genomic dysregulation of PI3K/AKT, RB, and p53 pathways. IDH-mutant
diffuse gliomas harbor either ATRX and TP53 mutation or 1p/19q
codeletion (frequently in combination with CIC mutation) in a mutually
exclusive manner. Histopathological trends regarding WHO grade and
morphology are also shown. Abbreviations: Astro, astrocytic; Oligo,
oligodendroglial.
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models involved the olfactory bulb, the final migratory destination
for subventricular zone (SVZ) precursors; this observation was con-
sistent with published work implicating neuroglial progenitors in
the SVZ as potential cells of origin for LGG.23,32 In all cases, high-
grade transformation occurred stochastically but frequently in as-
sociation with recurrent DNA copy number abnormalities involving
Met on murine chromosome 6.
Jason Huse (Memorial Sloan-Kettering Cancer Center) argued
that optimal preclinical models for LGG should be grounded in the
now-established genomic events driving disease-specific tumori-
genesis. While acknowledging that such experimental systems
havebeendifficult togenerate, particularly ingeneticallyengineered
mice, he proposed that a more faithful recapitulation of the precise
molecular and cellular context of low-grade gliomagenesis would
beessentialmovingforward, ifonlytodefinitively test the pathogen-
ic sufficiency of IDH1/2, ATRX, CIC, FUBP1 mutations. Reviewing
recent literature, he stressed the importance of targeting trans-
formative events to SVZ neuroglial progenitors, the likely cells of
origin for LGG. He also presented in vitro systems based on trans-
formed human astrocytes and cultured murine neural stem cells,
which appear to effectively model many of the core biological prop-
erties characterizing IDH-mutant gliomagenesis.
Clinical Trials and Novel Therapeutics
Multiple sessionsat the LGGResearchWorkshop were devotedtothe
subject of clinical trials for LGG, with a focus on promising therapeut-
ic agents and more effective study design. The phosphatidy
linositol-3-kinase (PI3K)/AKT/mammalian target of rapamycin
(mTOR) signaling network has been repeatedly implicated in
glioma biology over the past decade.33,34 However, a defined role
for the inhibition of this pathway in the treatment of LGG remains
to be established. Patrick Wen (Dana Farber Cancer Institute)
addressed this and other issues in his talk covering targeted therap-
ies for glioma. First, he described an ongoing trial of BKM120, an oral
pan-class I PI3K inhibitor, in patients with recurrent GBM in which he
highlighted design elements, such as specific molecular enrollment
criteria, that will likely improve study sensitivity. He also discussed
the promise of targeting the RAS/mitogen activated protein kinase
(MAPK) signaling network in selected pediatric and adult low-grade
glioma variants, such as ganglioglioma and pleomorphic
xanthoastrocytoma, which have recently been shown to frequently
and, in some cases invariably, harbor molecular abnormalities in
BRAF, a central pathway constituent.35,36 Finally, he discussed how
to best construct LGG trials, arguing that radiographic response
and/or PFS each represent superior endpoints to overall survival in
this specific disease context, given the extended clinical course
exhibited by many patients. In doing so, he reviewed the recently
published Response Assessment in Neuro-Oncology (RANO) criteria
for LGG and how they differ from those typically employed for GBM
and other high-grade gliomas, notably in their incorporation of
minor response criteria and considerations of patient-reported out-
comes and seizure control.37
Daphne Haas-Kogan presented preliminary findings from an
ongoing phase II trial of the mTOR inhibitor everolimus in recurrent
LGG. In this study, patients with histopathological evidence of recur-
rence and/or progression were treated with oral everolimus daily fol-
lowed by clinical and radiographic monitoring every 2–3 months.
PI3K pathway activation was assessed immunohistochemically
using a numberof markers including phospho-PRAS40, phospho-S6,
and PTEN. Interestingly, early results suggest increased PFS in
patients whose tumors are positive for phospho-PRAS40, presum-
ably indicating PI3K pathway activity. Should this correlation
persist when the data are fully mature, it would potentially guide
the management of LGG in the recurrent setting.
Much attention at the LGG Research Workshop was paid to the
prospect of targeting therapies to the mutant IDH protein that es-
sentially defines LGG pathogenesis. Kate Yen (Agios Pharmaceuti-
cals) detailed the results of recent preclinical work on AGI-5198, a
selective inhibitor of mutant IDH1.38 At nanomolar levels,
AGI-5198 appears to abrogate 2HG production, re-establish
normal differentiation processes in IDH1-mutant cells, and impair
the growth of IDH1-mutant xenografts in mice. Moreover, inhibition
of mutant IDH1 partially reverts some of the epigenomic alterations
induced by elevated 2HG. These promising results indicate that tar-
geting mutant IDH may prove to be a viable treatment strategy for
LGG and pave the way for clinical trials to formally address this pos-
sibility.
Tim Cloughesy (University of California, Los Angeles) then dis-
cussed clinical trial design for mutant IDH inhibitors. He raised
several important questions regarding pharmacodynamic valid-
ation, patient enrollment criteria, and efficacy assessments. For
Table 1. Clinical trials discussed in this meeting report
Title/Description Status NCI Registration # Additional ID #
A Phase II Study of Observation in Favorable Low-Grade Glioma and a Phase II Study of
Radiation With or Without PCV Chemotherapy in Unfavorable Low-grade Glioma
Closed NCT00003375 RTOG 9802
Natural History of Postoperative Cognitive Function, Quality of Life, and Seizure Control in
Patients With Supratentorial Low-Risk Grade II Glioma
Active NCT01417507 RTOG 0925
Phase III Randomized Comparison of Early vs No or Late Radiotherapy in Adult Patients
with Grade I/II Supratentorial Astrocytomas and Oligodendrogliomas
Closed EORTC 22845
Phase III Randomized Comparison of Two Radiotherapy Doses Following Surgery in
Adults with Grade I/II Supratentorial Astrocytoma and Oligodendroglioma
Closed EORTC 22844
Radiation Therapy or Temozolomide in Treating Patients With Gliomas Closed NCT00182819 EORTC 22033-26033
A Phase II Study of BKM 120 for Patients With Recurrent Glioblastoma and
Activated PI3K Pathway
Active NCT01339052
Phase II Trial of RAD001 in Patients With Recurrent Low Grade Glioma Active NCT00823459
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instance, what patient pools (eg, newly diagnosed LGG, recurrent/
treated secondary GBM, etc.) are optimally suited for mutant IDH1
inhibitor trials at the phase I and/or proof-of-concept stages? Can
2HG serve as a pharmacodynamic marker, can it be assessed non-
invasively, and will its levels correlate with disease response?
Finally, what constitutes the optimal endpoint for efficacy trials
(eg, response, PFS, etc.), and how should such endpoints be
assessed? He then presented a series of hypothetical trial struc-
tures that might effectively address these and other related
issues. In doing so, he alluded to the vital importance of radio-
graphic assessment for both pharmacodynamic and clinical end-
point determinations. Sarah Nelson (University of California,
San Francisco) spoke at greater length on this subject and
described recently successful efforts to detect 2HG by magnetic
resonance spectroscopy.39 She also covered progress in the devel-
opment of other agents for imaging metabolic markers such as
hyperpolarized 13C-labeled pyruvate and a-ketoglutarate.40
Personalizing the Management of Low-grade Glioma
As therapeutic regimens for LGG evolve in the ensuing years, study-
ing the biological behaviorof these tumors in the context of therapy
will become increasingly important. Addressing this subject,
Joseph Costello (University of California, San Francisco) presented
recent data from his group that described patterns of genomic
alterations acquired by LGGs during treatment with cytotoxic
chemotherapy. In a sample cohort consisting of case-matched
pairs of astrocytic LGGs, each consisting of one WHO grade II or
III tumor and the WHO grade IV GBM into which it evolved,
he found that 6 of 8 patients receiving temozolomide each
acquired more than 1 000 novel mutations prior to their tumors re-
curring as GBMs. By contrast, recurrences of all grades in the
remaining 16 sample pairs harbored less than 75 somatic muta-
tions each. Temozolomide-associated mutations were highly
enriched in C:G . T:A transitions, consistent with their induction
by alkylating agent therapy and frequently affected key amino
acids in constituents of bona fide oncogenic networks (eg, RB
and PI3K signaling pathways). These findings raise important ques-
tions regarding the most appropriate use of chemotherapy in LGGs
and how best to therapeutically manage genomic consequences
at recurrence.
Fine-tuning treatment regimens around the molecular evolu-
tion of specific tumors will require the routine employment of
high-throughput genomic technology in the clinical setting. In a
talk prepared by Marco Marra (British Columbia Cancer Agency),
Stephen Yip reported on early experiences with clinical genomics
at their institution. He described a 5- to 6-week workflow encom-
passing tumor biopsy, biomaterial extraction, sequencing (some
combination of targeted capture sequencing, whole genome
sequencing, and RNA sequencing), data analysis, therapeutic
recommendations, and final reporting. Through a series of case
studies, he then touched on some of the significant lessons
learned during the initial implementation of this pipeline. For in-
stance, biopsies from recurrences frequently yielded substantially
different genomic profiles than their respective primary tumors,
emphasizing the importance of adequate sampling for thorough
analysis. Moreover, genomic alterations could be selected by spe-
cific therapeutic regimens. Finally, and perhaps most significantly,
they found that genomic profiling could both inform diagnosis and
alter treatment approach.
Concluding Remarks
The recent molecularcharacterization of LGG has provided not only
a clarified framework for the conceptualization of these tumors but
has also revealed pathways for the development of more effective
targeted therapeutics. Both of these factors should dramatically
accelerate the pace of LGG research, with significant changes in
clinical management hopefully not far behind. As the process of
therapeutic refinement moves forward, more effective preclinical
models and optimal clinical trial design will be absolutely crucial,
as will the ready availability of sophisticated genomic technology
in the clinical environment. Moreover, multidisciplinary and inter-
national collaborative efforts will be critical to address the broad
aspects of LGG. While these are exciting times indeed, much
work remains to be done.
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